Home Featured Page 140

Featured

Latest

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Weekly Psychedelic Policy Briefing – August 9, 2026

Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from...

Bright Minds Biosciences Announces Resignation of Board Member

Jaguar Health and Filament Health, with Funding from One Small Planet,...

Psychedelic Research Bulletin: December 2022

Optimi Health Announces Re-Appointments to Board of Directors

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for...

PT381 – DMT, Hierarchies of Complexity, and Reality Switch Technologies

EDITOR PICKS

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Weekly Psychedelic Policy Briefing – August 9, 2026

Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from...

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from...

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from...

Bright Minds Biosciences Announces Resignation of Board Member

Jaguar Health and Filament Health, with Funding from One Small Planet,...

Psychedelic Research Bulletin: December 2022

Optimi Health Announces Re-Appointments to Board of Directors

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for...

PT381 – DMT, Hierarchies of Complexity, and Reality Switch Technologies

EDITOR PICKS

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY